Compare AGIO & BLKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGIO | BLKB |
|---|---|---|
| Founded | 2007 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2013 | 2004 |
| Metric | AGIO | BLKB |
|---|---|---|
| Price | $35.65 | $27.08 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 3 |
| Target Price | $38.88 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 1.0M | 878.1K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 142.32 |
| EPS | N/A | ★ 0.67 |
| Revenue | ★ $43,011,000.00 | N/A |
| Revenue This Year | $76.75 | $6.26 |
| Revenue Next Year | $170.73 | $4.25 |
| P/E Ratio | ★ N/A | $39.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.24 | $25.58 |
| 52 Week High | $46.00 | $74.86 |
| Indicator | AGIO | BLKB |
|---|---|---|
| Relative Strength Index (RSI) | 74.22 | 37.12 |
| Support Level | $26.71 | N/A |
| Resistance Level | $36.07 | $32.93 |
| Average True Range (ATR) | 1.44 | 1.43 |
| MACD | 0.79 | 0.13 |
| Stochastic Oscillator | 98.76 | 34.98 |
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.